Daniel M. Halperin

Daniel M. Halperin

Family Medicine

36 Linden Ave NE
Atlanta, GA 30308

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 98 publications

Author Correction: AhR inhibition promotes axon regeneration via a stress-growth switch.

Author Correction: AhR inhibition promotes axon regeneration via a stress-growth switch.

Journal: Nature

Published: September 07, 2026

Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues.

Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 02, 2026

Releasing the neuronal brake: Inhibiting AhR to enhance axon regeneration.

Releasing the neuronal brake: Inhibiting AhR to enhance axon regeneration.

Journal: Clinical and translational medicine

Published: June 16, 2026

Robust response to pembrolizumab in temozolomide-associated hypermutated and microsatellite instability-high functional pancreatic neuroendocrine tumor.

Robust response to pembrolizumab in temozolomide-associated hypermutated and microsatellite instability-high functional pancreatic neuroendocrine tumor.

Journal: The oncologist

Published: April 12, 2026

Clinical Validity of NETest2.0® in Surveillance of Neuroendocrine Tumor Patients: Evidence from a NET Registry Study (NCT02270567).

Clinical Validity of NETest2.0® in Surveillance of Neuroendocrine Tumor Patients: Evidence from a NET Registry Study (NCT02270567).

Journal: Cancers

Published: April 07, 2026

Grade Progression and High-Grade Transformation in Neuroendocrine Neoplasms.

Grade Progression and High-Grade Transformation in Neuroendocrine Neoplasms.

Journal: Endocrine-related cancer

Published: January 13, 2026

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial.

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial.

Journal: EClinicalMedicine

Published: January 07, 2026

Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor.

Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor.

Journal: Current oncology (Toronto, Ont.)

Published: December 23, 2025

Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy.

Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy.

Journal: Endocrine-related cancer

Published: November 24, 2025

Cortical tension as a mechanical barrier to safeguard against premature differentiation during neurogenesis.

Cortical tension as a mechanical barrier to safeguard against premature differentiation during neurogenesis.

Journal: Research square

Published: November 24, 2025

Survival trends in the management of carcinoid heart disease among patients with neuroendocrine neoplasms.

Survival trends in the management of carcinoid heart disease among patients with neuroendocrine neoplasms.

Journal: Cardio-oncology (London, England)

Published: November 19, 2025

Cortical tension as a mechanical barrier to safeguard against premature differentiation during neurogenesis.

Cortical tension as a mechanical barrier to safeguard against premature differentiation during neurogenesis.

Journal: bioRxiv : the preprint server for biology

Published: September 26, 2025

Showing 1-12 of 98

Last Updated: 09/26/2026